Seres Therapeutics, Inc.
MCRB Nasdaq
SEC CIK 1609809
Follow Seres Therapeutics
Weekly email: filings, results
Revenue, last quarter
$593K
+68.9% vs same quarter last year
Net income
−$16.3M
−298.5% vs same quarter last year
EPS, diluted
−$1.63
−273.4% vs same quarter last year
Operating cash flow
−$10.5M
−574.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $789K | $5.7M |
| FY24 | $0 | $136K |
| FY23 | $0 | −$113.7M |
| FY22 | $7.1M | −$250.2M |
| FY21 | $143.9M | −$65.6M |
| FY20 | $11.9M | −$89.1M |
| FY19 | $27.2M | −$70.3M |
| FY18 | $26.9M | −$98.9M |
| FY17 | $32.1M | −$89.4M |
| FY16 | $21.8M | −$91.6M |
| FY15 | $0 | −$54.8M |
| FY14 | - | −$16.7M |
| FY13 | - | −$6.1M |
| FY12 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −11910.1% | 721.9% |
| FY24 | - | - |
| FY23 | - | - |
| FY22 | −2524% | −3509.5% |
| FY21 | −44.8% | −45.6% |
| FY20 | −740.8% | −749.2% |
| FY19 | −264.4% | −258.5% |
| FY18 | −372.6% | −367.6% |
| FY17 | −284.7% | −278.4% |
| FY16 | −426.5% | −420.7% |
| FY15 | - | - |
| FY14 | - | - |
| FY13 | - | - |
| FY12 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $865K |
| FY24 | −$149M |
| FY23 | −$125.3M |
| FY22 | −$238.6M |
| FY21 | −$2.9M |
| FY20 | −$94.2M |
| FY19 | −$77.5M |
| FY18 | −$64.8M |
| FY17 | −$80.2M |
| FY16 | $22.4M |
| FY15 | −$45.2M |
| FY14 | −$11.4M |
| FY13 | −$5.5M |
| FY12 | - |
- Seres Therapeutics
- Healthcare median
Show the numbers
| Year | Seres Therapeutics | Healthcare median |
|---|---|---|
| FY25 | 721.9% | −30.6% |
| FY24 | - | −47% |
| FY23 | - | −58% |
| FY22 | −3509.5% | −80.4% |
| FY21 | −45.6% | −71.8% |
| FY20 | −749.2% | −62.2% |
| FY19 | −258.5% | −46.2% |
| FY18 | −367.6% | −49.6% |
| FY17 | −278.4% | −45.9% |
| FY16 | −420.7% | −36% |
| FY15 | - | −37.8% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |
| FY12 | - | −29.1% |